How Will Our Practice Change After the CLEAR Outcomes Trial?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Metabolic Disorders

Background:

• Bempedoic acid is a novel therapeutic agent targeting low-density lipoprotein cholesterol (LDL-C) reduction.
• It inhibits ATP citrate lyase in the liver, decreasing cholesterol synthesis and potentially avoiding statin-associated muscle symptoms.

Purpose of the Study:

• To review the development of bempedoic acid.
• To present findings from clinical trials.
• To discuss the clinical implications of bempedoic acid therapy.

Main Methods:

• Review of preclinical and clinical trial data for bempedoic acid.
• Analysis of efficacy in lowering LDL-C and high-sensitivity C-reactive protein.
• Evaluation of safety and adverse events, including the CLEAR Outcomes trial.

Main Results:

• Bempedoic acid monotherapy lowered LDL-C by 20-30%; combined with ezetimibe, it achieved 40-50% reduction.
• High-sensitivity C-reactive protein decreased by 20-30%.
• The CLEAR Outcomes trial showed a reduction in major adverse cardiovascular events in high-risk patients.

Conclusions:

• Bempedoic acid is an effective option for lowering LDL-C and reducing cardiovascular risk.
• It provides an alternative for patients intolerant to statins.
• Potential adverse events include elevated hepatic transaminase and creatinine, gout, and cholelithiasis.